Correction: Corrigendum: Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

E. M. Alexandrova, A. R. Yallowitz, D. Li, S. Xu, R. Schulz, D. A. Proia, G. Lozano, M. Dobbelstein and U. M. Moll

Nature, 2015, vol. 527, issue 7578, 398-398

Abstract: Nature 523, 352–356 (2015); doi: 10.1038/nature14430 In this Letter on page 353, the words ‘substrate Hsp90’ should have been included in this sentence as follows: “Likewise, histone deacetylase inhibitors, including FDA-approved SAHA, are promising anti-cancer drugs whose actions involve hyperacetylation of histone and select non-histone targets including HDAC6 substrate Hsp90, thus indirectly inhibiting Hsp90 (ref.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/nature15720 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:527:y:2015:i:7578:d:10.1038_nature15720

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature15720

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().